Details of the Drug

General Information of Drug (ID: DMVP5YE)

Drug Name
Doxorubicin
Synonyms
doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Breast cancer 2C60-2C65 Phase 2 [4]
Tumour 2A00-2F9Z Investigative [5]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 543.5
Topological Polar Surface Area (xlogp) 1.3
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [6]
Clearance
The drug present in the plasma can be removed from the body at the rate of 15 mL/min/kg [7]
Elimination
3.5% of drug is excreted from urine in the unchanged form [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 20 - 48 hours [7]
Metabolism
The drug is metabolized via several oxidoreductases to form a doxirubicin-semiquinone radical [8]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.47076 micromolar/kg/day [9]
Unbound Fraction
The unbound fraction of drug in plasma is 0.28% [7]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 22 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [6]
Chemical Identifiers
Formula
C27H29NO11
IUPAC Name
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
InChI
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1
InChIKey
AOJJSUZBOXZQNB-TZSSRYMLSA-N
Cross-matching ID
PubChem CID
31703
ChEBI ID
CHEBI:28748
CAS Number
23214-92-8
DrugBank ID
DB00997
TTD ID
D07VLY
VARIDT ID
DR00301
INTEDE ID
DR0546

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [10]
TERT messenger RNA (TERT mRNA) TTQY2EJ TERT_HUMAN Not Available [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
ATP-binding cassette sub-family B member 8 (ABCB8) DT0KQND ABCB8_HUMAN Substrate [11]
ATP-binding cassette sub-family B member 5 (ABCB5) DTKVEXO ABCB5_HUMAN Substrate [12]
Fly-like putative transporter 2 (SLC22A16) DTPATLS S22AG_HUMAN Substrate [13]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [14]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [15]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [16]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [17]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [18]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [19]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [20]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [21]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [22]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [23]
Nitric oxide synthase inducible (NOS2) DE3C1JY NOS2_HUMAN Substrate [24]
Nitric oxide synthase endothelial (NOS3) DE708H2 NOS3_HUMAN Substrate [24]
NADPH-cytochrome P450 reductase (CPR)
Main DME 		DE3N2FM NCPR_HUMAN Substrate [25]
Aldo-keto reductase 1C3 (AKR1C3) DEGQTXO AK1C3_HUMAN Substrate [26]
Nitric oxide synthase brain (NOS1) DEYEK78 NOS1_HUMAN Substrate [24]
Aldo-keto reductase 1A1 (AKR1A1) DED2FW3 AK1A1_HUMAN Substrate [27]
Xanthine dehydrogenase/oxidase (XDH)
Main DME 		DECG04O XDH_HUMAN Substrate [28]
NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3) DE741FI NDUS3_HUMAN Substrate [23]
NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2) DEKX5CD NDUS2_HUMAN Substrate [23]
Methionine synthase reductase (MTRR) DE6NIY9 MTRR_HUMAN Substrate [29]
Succinic semialdehyde reductase (AKR7A2) DE4G629 ARK72_HUMAN Substrate [30]
NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7) DEIW03B NDUS7_HUMAN Substrate [23]
NADH dehydrogenase (nuoE) DEAMEF2 J9VB37_9ACTN Substrate [31]
Molybdopterin-dependent enzyme (molD) DEME01W A0A327UAE0_9ACTN Substrate [32]
Molybdopterin-dependent enzyme (molD) DEYSOD0 A0A327SQQ7_9ACTN Substrate [32]
Molybdopterin-dependent enzyme (molD) DE1QMDG A0A327U7N1_9ACTN Substrate [32]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxorubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Doxorubicin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [133]
Ifosfamide DMCT3I8 Moderate Additive myelosuppressive effects by the combination of Doxorubicin and Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [134]
Armodafinil DMGB035 Minor Increased metabolism of Doxorubicin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [135]
LEE011 DMMX75K Major Decreased metabolism of Doxorubicin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [136]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Doxorubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [136]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [137]
⏷ Show the Full List of 6 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Doxorubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Doxorubicin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [137]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [138]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Midostaurin. Acute myeloid leukaemia [2A60] [136]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Idarubicin. Acute myeloid leukaemia [2A60] [136]
Arn-509 DMT81LZ Moderate Increased metabolism of Doxorubicin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [137]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [139]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Oliceridine. Acute pain [MG31] [136]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ivabradine. Angina pectoris [BA40] [137]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Bepridil. Angina pectoris [BA40] [136]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Dronedarone. Angina pectoris [BA40] [136]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Doxorubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [140]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Cilostazol. Arterial occlusive disease [BD40] [136]
Posaconazole DMUL5EW Moderate Decreased metabolism of Doxorubicin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [137]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Levalbuterol. Asthma [CA23] [141]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Pirbuterol. Asthma [CA23] [142]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Salbutamol. Asthma [CA23] [141]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Roflumilast. Asthma [CA23] [137]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [137]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Desipramine. Attention deficit hyperactivity disorder [6A05] [136]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Ofloxacin. Bacterial infection [1A00-1C4Z] [143]
Dalfopristin DM4LTKV Major Decreased metabolism of Doxorubicin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [144]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Clarithromycin. Bacterial infection [1A00-1C4Z] [145]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Doxorubicin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [136]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Doxorubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [143]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [143]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Norfloxacin. Bacterial infection [1A00-1C4Z] [143]
ABT-492 DMJFD2I Minor Decreased absorption of Doxorubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [146]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Levofloxacin. Bacterial infection [1A00-1C4Z] [143]
Ag-221 DMS0ZBI Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [133]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Retigabine. Behcet disease [4A62] [136]
Erdafitinib DMI782S Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [147]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Doxorubicin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [137]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Eribulin. Breast cancer [2C60-2C6Y] [136]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Lapatinib. Breast cancer [2C60-2C6Y] [145]
Tucatinib DMBESUA Moderate Decreased metabolism of Doxorubicin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [148]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [149]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [142]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [141]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [142]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [142]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Isoproterenol. Conduction disorder [BC63] [141]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Halothane. Corneal disease [9A76-9A78] [136]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Sevoflurane. Corneal disease [9A76-9A78] [136]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Probucol. Coronary atherosclerosis [BA80] [136]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Doxorubicin and Pasireotide. Cushing syndrome [5A70] [136]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Osilodrostat. Cushing syndrome [5A70] [137]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Doxorubicin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [150]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Doxorubicin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [151]
MK-8228 DMOB58Q Moderate Decreased metabolism of Doxorubicin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [152]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Sertraline. Depression [6A70-6A7Z] [136]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Doxorubicin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [153]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Doxorubicin and Escitalopram. Depression [6A70-6A7Z] [136]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Clomipramine. Depression [6A70-6A7Z] [136]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Doxepin. Depression [6A70-6A7Z] [136]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [136]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Doxorubicin and Deutetrabenazine. Dystonic disorder [8A02] [154]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Ingrezza. Dystonic disorder [8A02] [155]
Cenobamate DMGOVHA Moderate Increased metabolism of Doxorubicin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [137]
Stiripentol DMMSDOY Moderate Decreased metabolism of Doxorubicin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [156]
Rufinamide DMWE60C Moderate Increased metabolism of Doxorubicin caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [137]
Phenobarbital DMXZOCG Moderate Increased metabolism of Doxorubicin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [137]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Doxorubicin caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [137]
Tazemetostat DMWP1BH Moderate Increased metabolism of Doxorubicin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [157]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Solifenacin. Functional bladder disorder [GC50] [136]
Itraconazole DMCR1MV Moderate Decreased metabolism of Doxorubicin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [158]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Ketoconazole. Fungal infection [1F29-1F2F] [136]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [136]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Doxorubicin caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [137]
Rifampin DMA8J1G Moderate Increased metabolism of Doxorubicin caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [150]
Rifapentine DMCHV4I Moderate Increased metabolism of Doxorubicin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [137]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [159]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Doxorubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [160]
Etravirine DMGV8QU Moderate Increased metabolism of Doxorubicin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [137]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [136]
Darunavir DMN3GCH Moderate Decreased metabolism of Doxorubicin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [161]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Doxorubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [162]
BMS-201038 DMQTAGO Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [163]
Tolvaptan DMIWFRL Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [133]
Givosiran DM5PFIJ Moderate Decreased metabolism of Doxorubicin caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [164]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Doxorubicin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [165]
Amobarbital DM0GQ8N Moderate Increased metabolism of Doxorubicin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [137]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [137]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Denosumab. Low bone mass disorder [FB83] [166]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Doxorubicin and Crizotinib. Lung cancer [2C25] [167]
Brigatinib DM7W94S Moderate Increased metabolism of Doxorubicin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [137]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Doxorubicin and Ceritinib. Lung cancer [2C25] [136]
PF-06463922 DMKM7EW Moderate Increased metabolism of Doxorubicin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [150]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Doxorubicin caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [168]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Doxorubicin and Osimertinib. Lung cancer [2C25] [169]
Capmatinib DMYCXKL Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [170]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Doxorubicin and Selpercatinib. Lung cancer [2C25] [137]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Doxorubicin and Lumefantrine. Malaria [1F40-1F45] [133]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Doxorubicin and Halofantrine. Malaria [1F40-1F45] [171]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Doxorubicin and Hydroxychloroquine. Malaria [1F40-1F45] [172]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Primaquine. Malaria [1F40-1F45] [136]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [137]
Idelalisib DM602WT Moderate Decreased metabolism of Doxorubicin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [173]
IPI-145 DMWA24P Moderate Decreased metabolism of Doxorubicin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [174]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [175]
Mercaptopurine DMTM2IK Moderate Increased risk of hepatotoxicity by the combination of Doxorubicin and Mercaptopurine. Mature B-cell lymphoma [2A85] [134]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Vemurafenib. Melanoma [2C30] [136]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and LGX818. Melanoma [2C30] [176]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Doxorubicin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [137]
Lasmiditan DMXLVDT Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [177]
Exjade DMHPRWG Moderate Increased metabolism of Doxorubicin caused by Exjade mediated induction of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [137]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Doxorubicin and Panobinostat. Multiple myeloma [2A83] [178]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Doxorubicin and Thalidomide. Multiple myeloma [2A83] [179]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Tecfidera. Multiple sclerosis [8A40] [180]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Doxorubicin and Siponimod. Multiple sclerosis [8A40] [133]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Fingolimod. Multiple sclerosis [8A40] [181]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Ocrelizumab. Multiple sclerosis [8A40] [182]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Doxorubicin and Ozanimod. Multiple sclerosis [8A40] [137]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Romidepsin. Mycosis fungoides [2B01] [136]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Doxorubicin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [137]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Doxorubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [136]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [183]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Doxorubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [184]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Promethazine. Nausea/vomiting [MD90] [136]
Rolapitant DM8XP26 Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [185]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Entrectinib. Non-small cell lung cancer [2C25] [133]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [137]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Lofexidine. Opioid use disorder [6C43] [136]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Doxorubicin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [186]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Triclabendazole. Parasitic worm infestation [1F90] [136]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Pimavanserin. Parkinsonism [8A00] [187]
Abametapir DM2RX0I Moderate Decreased metabolism of Doxorubicin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [188]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Doxorubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [189]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Lefamulin. Pneumonia [CA40] [190]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Doxorubicin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [191]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Degarelix. Prostate cancer [2C82] [137]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and ABIRATERONE. Prostate cancer [2C82] [137]
Enzalutamide DMGL19D Moderate Increased metabolism of Doxorubicin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [137]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Relugolix. Prostate cancer [2C82] [137]
Darolutamide DMV7YFT Moderate Decreased clearance of Doxorubicin due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [192]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Bicalutamide. Prostate cancer [2C82] [137]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Levomepromazine. Psychotic disorder [6A20-6A25] [136]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Doxorubicin and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [193]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [194]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Canakinumab. Rheumatoid arthritis [FA20] [195]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Doxorubicin and Rilonacept. Rheumatoid arthritis [FA20] [195]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Doxorubicin and Golimumab. Rheumatoid arthritis [FA20] [196]
Dexamethasone DMMWZET Moderate Increased metabolism of Doxorubicin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [137]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Doxorubicin and Leflunomide. Rheumatoid arthritis [FA20] [162]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Quetiapine. Schizophrenia [6A20] [136]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Aripiprazole. Schizophrenia [6A20] [133]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Doxorubicin and Iloperidone. Schizophrenia [6A20] [136]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Paliperidone. Schizophrenia [6A20] [136]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Doxorubicin and Amisulpride. Schizophrenia [6A20] [197]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Asenapine. Schizophrenia [6A20] [136]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Doxorubicin and Pimozide. Schizophrenia [6A20] [137]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Doxorubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [198]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Doxorubicin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [199]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Doxorubicin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [137]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Pitolisant. Somnolence [MG42] [137]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [136]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Doxorubicin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [200]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Lenvatinib. Thyroid cancer [2D10] [136]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Cabozantinib. Thyroid cancer [2D10] [137]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Doxorubicin and Papaverine. Tonus and reflex abnormality [MB47] [201]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [145]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Procainamide. Ventricular tachyarrhythmia [BC71] [136]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Propafenone. Ventricular tachyarrhythmia [BC71] [136]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Doxorubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [136]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Doxorubicin and Amiodarone. Ventricular tachyarrhythmia [BC71] [136]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Doxorubicin and Ganciclovir. Virus infection [1A24-1D9Z] [133]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Doxorubicin and Valganciclovir. Virus infection [1A24-1D9Z] [133]
⏷ Show the Full List of 166 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Histidine E00106 6274 Antioxidant; Buffering agent
Hydrochloric acid E00015 313 Acidulant
Ammonium sulfate E00490 6097028 Buffering agent
Cholesterol E00092 5997 Emollient; Emulsifying agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Soybean lecithin E00637 Not Available Other agent
Water E00035 962 Solvent
N-(carbonyl-methoxypolyethylene glycol 2000)-1 E00685 86278269 Other agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Doxorubicin Hydrochloride 20mg/10ml liposomaldispersion 20mg/10ml Liposomaldispersion Intravenous
Doxorubicin Hydrochloride 10mg/5ml solution 10mg/5ml Solution Intravenous
Doxorubicin Hydrochloride 20mg/10ml solution 20mg/10ml Solution Intravenous
Doxorubicin Hydrochloride 50mg/25ml solution 50mg/25ml Solution Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
4 Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
5 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
6 BDDCS applied to over 900 drugs
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
9 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
10 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
11 ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
12 ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
13 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
14 Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
15 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
16 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
17 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
18 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
19 Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
20 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
21 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
23 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
24 The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
25 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
26 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
27 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
28 Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
29 Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
30 Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
31 Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
32 Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
33 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
34 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
35 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
36 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
37 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
38 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
39 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
40 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
41 Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
42 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
43 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
44 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
45 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
46 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
47 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
48 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
49 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
50 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
51 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
52 Drug Interactions Flockhart Table
53 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
54 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
55 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
56 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
57 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
58 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
59 Molecular characterization and taurine regulation of two novel CDOs (CDO1 and CDO2) from Carassius auratus. Comp Biochem Physiol B Biochem Mol Biol. 2019 Sep;235:54-61.
60 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
61 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
62 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
63 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
64 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
65 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
66 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
67 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
68 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
69 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
70 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
71 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
72 Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
73 Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
74 The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
75 In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
76 Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
77 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
78 Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
79 Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
80 Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B. 2008 Feb;9(2):93-9.
81 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
82 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
83 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
84 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
85 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
86 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
87 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
88 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
89 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
90 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
91 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
92 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
93 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
94 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
95 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
96 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
97 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
98 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
99 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
100 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
101 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
102 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
103 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
104 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
105 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
106 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
107 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
108 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
109 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
110 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
111 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
112 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
113 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
114 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
115 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
116 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
117 Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
118 AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
119 Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
120 Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
121 Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
122 Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
123 Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
124 The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
125 Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
126 Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
127 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
128 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
129 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
130 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
131 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
132 Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
133 Cerner Multum, Inc. "Australian Product Information.".
134 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
135 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
136 Canadian Pharmacists Association.
137 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
138 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
139 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
140 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
141 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
142 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
143 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
144 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
145 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
146 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
147 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
148 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
149 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
150 Product Information. Adriamycin PFS (doxorubicin). Pharmacia and Upjohn, Kalamazoo, MI.
151 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
152 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
153 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
154 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
155 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
156 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
157 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
158 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
159 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
160 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
161 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
162 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
163 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
164 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
165 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
166 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
167 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
168 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
169 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
170 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
171 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
172 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
173 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
174 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
175 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
176 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
177 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
178 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
179 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
180 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
181 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
182 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
183 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
184 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
185 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
186 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
187 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
188 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
189 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
190 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
191 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
192 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
193 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
194 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
195 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
196 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
197 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
198 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
199 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
200 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
201 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]